Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
1
institution
Market cap
$282.6M
45M shares
52-week range
$4.01 β $54.97
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
www.sionnatx.comNo one on the platform currently holds SION.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 14,600 | $429.4K |
No one on the platform has traded SION yet.
$SION 45% so far π°πΊπ° My long position doing greatπ
View on StockTwits β$SION all the app showing different price..webulls 6.84, yahoo 6.54,, stcktweet 6.65 lol
View on StockTwits β$SION Top funds own a bunch! I will definitely hold a few long term.
View on StockTwits β$SION tomorrow might go down below 6..no volume at all..
View on StockTwits β$CAPR the same thing will happen to $HTZ $SION and $TENX , watch it!!!
View on StockTwits β$TENX $CAPR $SION pharmaceutical stocks just started realizing value after recent steep dropβ¦ 2X is on the way
View on StockTwits β$SION rsi is 19.92 on the 4 hour. Seems a tad oversold don't you think?
View on StockTwits β$SION those who want this going down will have to wait many years from now. π―π§
View on StockTwits β$SPCX could have bought $SION or $ZONE instead π€·ββοΈπ€π€π€π€π€
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $0 | β | $-2.59 | $-3.17β$-2.17 | β | 7 |
| 2027 | $3M | β | $-2.83 | $-3.84β$-2.26 | β | 7 |
| 2028 | $5M | +83.3% | $-3.25 | $-4.11β$-2.10 | β | 8 |
| 2029 | $33M | +552.0% | $-2.97 | $-2.97β$-2.97 | β | 5 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 3 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.65 | $-0.66 | -1.5% |
| 2026-05-12 | $-0.52 | $-0.60 | -15.4% |
| 2026-03-02 | $-0.54 | $-0.46 | +14.7% |
| 2025-11-05 | $-0.52 | $-0.46 | +11.5% |
| 2025-08-11 | $-0.68 | $-0.41 | +39.7% |
| 2025-05-12 | $-0.45 | $-0.62 | -37.8% |
| 2025-03-20 | $-1.28 | $-3.38 | -164.8% |
| $2.8B |
| β |
| IMNMImmunome, Inc. | $26.42 | -5.61% | $2.5B | β |
| JANXJanux Therapeutics, Inc. | $16.00 | -4.02% | $976M | β |
Source: Financial Modeling Prep Β· peers by sector/industry